Vontobel Holding Ltd. Acquires 28,000 Shares of PDS Biotechnology Co. (NASDAQ:PDSB)

Vontobel Holding Ltd. increased its stake in shares of PDS Biotechnology Co. (NASDAQ:PDSB) by 233.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 40,000 shares of the company’s stock after acquiring an additional 28,000 shares during the quarter. Vontobel Holding Ltd. owned about 0.11% of PDS Biotechnology worth $153,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Kathleen S. Wright Associates Inc. acquired a new position in shares of PDS Biotechnology during the first quarter valued at about $28,000. Vanguard Group Inc. increased its stake in PDS Biotechnology by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after acquiring an additional 82,135 shares during the period. Inspirion Wealth Advisors LLC increased its stake in PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock valued at $1,054,000 after acquiring an additional 4,917 shares during the period. Tempus Wealth Planning LLC acquired a new position in PDS Biotechnology in the 2nd quarter valued at approximately $55,000. Finally, Ground Swell Capital LLC bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth approximately $67,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, PDS Biotechnology currently has a consensus rating of “Moderate Buy” and an average price target of $14.25.

PDS Biotechnology Trading Down 4.4 %

Shares of PDSB opened at $3.12 on Thursday. The stock has a 50 day simple moving average of $3.27 and a 200-day simple moving average of $3.27. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock has a market cap of $114.26 million, a PE ratio of -2.29 and a beta of 1.90. PDS Biotechnology Co. has a 1 year low of $2.53 and a 1 year high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. During the same period in the prior year, the firm earned ($0.37) EPS. On average, sell-side analysts predict that PDS Biotechnology Co. will post -1.24 EPS for the current fiscal year.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.